Skip to main content

Prolensa FDA Approval History

FDA Approved: Yes (First approved April 5, 2013)
Brand name: Prolensa
Generic name: bromfenac
Dosage form: Ophthalmic Solution
Company: Bausch + Lomb
Treatment for: Postoperative Ocular Inflammation

Prolensa (bromfenac ophthalmic solution) is a topical nonsteroidal anti-inflammatory indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Development timeline for Prolensa

Apr  8, 2013Approval Bausch + Lomb Receives FDA Approval for Prolensa

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.